1. Academic Validation
  2. Potent and selective xanthine-based inhibitors of phosphodiesterase 5

Potent and selective xanthine-based inhibitors of phosphodiesterase 5

  • Bioorg Med Chem Lett. 2007 Apr 15;17(8):2376-9. doi: 10.1016/j.bmcl.2006.11.019.
Nichola J Arnold 1 Ruth Arnold David Beer Gurdip Bhalay Stephen P Collingwood Sarah Craig Nicholas Devereux Mark Dodds Andrew R Dunstan Robin A Fairhurst David Farr Joseph D Fullerton Angela Glen Sylvie Gomez Sandra Haberthuer Julia D I Hatto Colin Howes Darryl Jones Thomas H Keller Beate Leuenberger Heinz E Moser Irene Muller Reto Naef Paul A Nicklin David A Sandham Katharine L Turner Morris F Tweed Simon J Watson Mauro Zurini
Affiliations

Affiliation

  • 1 Novartis Institutes of Biomedical Research, Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB, UK.
Abstract

Inhibitors of PDE5 are useful therapeutic agents for treatment of erectile dysfunction. A series of novel xanthine derivatives has been identified as potent inhibitors of PDE5, with good levels of selectivity against Other PDE isoforms, including PDE6. Studies in the dog indicate excellent oral bioavailability for compound 21.

Figures
Products